IL279987A - Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4 - Google Patents

Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4

Info

Publication number
IL279987A
IL279987A IL279987A IL27998721A IL279987A IL 279987 A IL279987 A IL 279987A IL 279987 A IL279987 A IL 279987A IL 27998721 A IL27998721 A IL 27998721A IL 279987 A IL279987 A IL 279987A
Authority
IL
Israel
Prior art keywords
antigen
compositions
binding site
methods related
engineered constructs
Prior art date
Application number
IL279987A
Other languages
English (en)
Hebrew (he)
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of IL279987A publication Critical patent/IL279987A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL279987A 2018-07-11 2021-01-06 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4 IL279987A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862696746P 2018-07-11 2018-07-11
PCT/US2019/041324 WO2020014429A2 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4

Publications (1)

Publication Number Publication Date
IL279987A true IL279987A (en) 2021-03-01

Family

ID=69142497

Family Applications (1)

Application Number Title Priority Date Filing Date
IL279987A IL279987A (en) 2018-07-11 2021-01-06 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4

Country Status (11)

Country Link
US (1) US20250346676A1 (https=)
EP (1) EP3820517A4 (https=)
JP (1) JP2021531756A (https=)
KR (1) KR20210042324A (https=)
CN (1) CN113164590A (https=)
AU (1) AU2019302662A1 (https=)
BR (1) BR112021000391A2 (https=)
CA (1) CA3105985A1 (https=)
IL (1) IL279987A (https=)
MX (1) MX2021000290A (https=)
WO (1) WO2020014429A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4463485A4 (en) * 2022-01-12 2026-02-25 Biomolecular Holdings Llc Tetrahedral antibodies
US20250084169A1 (en) 2022-01-12 2025-03-13 Biomolecular Holdings Llc Nk/monocyte engagers
WO2024221187A1 (en) * 2023-04-24 2024-10-31 Biomap Intelligence Technology Sg Pte.Ltd. Heteromultimer polypeptides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US20050287138A1 (en) * 2003-10-08 2005-12-29 Kyowa Hakko Kogyo Co., Ltd. CCR4-specific antibody composition
US20090304715A1 (en) * 2006-03-03 2009-12-10 Tokyo University Of Science Modified antibodies with enhanced biological activities
US8962806B2 (en) * 2007-12-28 2015-02-24 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
CA2766065C (en) * 2009-06-30 2020-07-21 Research Development Foundation Immunoglobulin fc polypeptides
AU2013256010B2 (en) * 2012-05-04 2018-01-04 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
WO2017151971A2 (en) * 2016-03-02 2017-09-08 Momenta Pharmaceuticals, Inc. METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
BR112018074056A2 (pt) * 2016-05-23 2019-03-06 Momenta Pharmaceuticals, Inc. composições e métodos relacionados a construtos de fc manipulados

Also Published As

Publication number Publication date
MX2021000290A (es) 2021-09-08
JP2021531756A (ja) 2021-11-25
EP3820517A2 (en) 2021-05-19
WO2020014429A2 (en) 2020-01-16
AU2019302662A1 (en) 2021-02-25
KR20210042324A (ko) 2021-04-19
US20250346676A1 (en) 2025-11-13
CA3105985A1 (en) 2020-01-16
CN113164590A (zh) 2021-07-23
BR112021000391A2 (pt) 2021-04-06
WO2020014429A3 (en) 2020-02-13
EP3820517A4 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
EP3673055A4 (en) RNA TARGETING METHODS AND COMPOSITIONS
DK3484514T3 (da) Compositions and methods related to engineered fc constructs
IL268895A (en) Compositions and methods for inhibition of lineage specific proteins
FI12008U1 (fi) Käsitelty ligniini ja sideainekoostumus
PL4074331T3 (pl) Kompozycje i sposoby internalizacji enzymów
DK3628161T3 (da) Synergistiske bakterielle sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
DK2861067T3 (da) Synergistiske sammensætninger til beskyttelsen af landbrugsafgrøder og anvendelsen deraf
DK2971167T3 (da) Sammensætninger og fremgangsmåder til targeting af nucleinsyre med nucleinsyrer
DK3019533T3 (da) Dobbeltspiraliserede immunoglobulinfusionproteiner og sammensætninger deraf
DK2816898T3 (da) Topiske sammensætninger omfattende fipronil og permethrin og fremgangsmåder til anvendelse
DK3394272T3 (da) Sammensætninger og fremgangsmåder til effektiv målretning af transgener
PL3293188T3 (pl) Silany i utwardzalne kompozycje obejmujące wskazane silany
EP3565595A4 (en) COMPOSITIONS AND METHODS ASSOCIATED WITH DOMAIN CONSTRUCTIONS OF BINDING TO MANIPULATED FC ANTIGEN
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
EP3262075C0 (en) NOVEL TFPI-BINDING ANTIBODY AND COMPOSITION COMPRISING SAME
IL279987A (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4
MA54143A (fr) Compositions et méthodes
IL279998A (en) Compositions and methods relating to engineered constructs with an antigen-binding site-FC
IL280014A (en) Compositions and methods relating to engineered constructs with an antigen-binding site FC targeting CTLA-4
SG10202107391YA (en) Compositions and methods related to engineered fc constructs
IL257458B1 (en) Dpep-1 binding compositions and methods of use
PL3638278T3 (pl) Kompozycje neuroprotekcyjne i ich zastosowanie
IL280044A (en) Compositions and methods relating to engineered constructs with an antigen-binding site-FC
IL280038A (en) Compositions and methods relating to engineered constructs with an antigen-binding site FC targeting PD-L1
DK3066204T3 (da) Sammensætninger og fremgangsmåder til fremstilling af genetisk modificerede dyr